Agora Open Science Trust

Agora Open Science Trust operates as a Canadian charity dedicated to accelerating the development of affordable new medicines through an open science model. It owns two key subsidiaries—M4K Pharma Inc. and M4ND Pharma Inc.—which focus on rare pediatric cancers and neurodegenerative diseases respectively. The lead program targets diffuse intrinsic pontine glioma with a kinase inhibitor currently in late preclinical development; additional programs are at earlier stages. The organization eschews patents in favor of regulatory exclusivity to ensure affordability and reinvests all proceeds into further open-science initiatives.